Literature DB >> 19966847

Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma.

S S Tykodi, L N Voong, E H Warren.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19966847      PMCID： PMC2922048          DOI： 10.1038/bmt.2009.338

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  9 in total

1.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

2.  Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe.

Authors:  L Barkholt; M Bregni; M Remberger; D Blaise; J Peccatori; G Massenkeil; P Pedrazzoli; A Zambelli; J-O Bay; S Francois; R Martino; C Bengala; M Brune; S Lenhoff; A Porcellini; M Falda; S Siena; T Demirer; D Niederwieser; O Ringdén
Journal:  Ann Oncol       Date:  2006-04-28       Impact factor: 32.976

3.  Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.

Authors:  Scott S Tykodi; Edus H Warren; John A Thompson; Stanley R Riddell; Richard W Childs; Brith E Otterud; Mark F Leppert; Rainer Storb; Brenda M Sandmaier
Journal:  Clin Cancer Res       Date:  2004-12-01       Impact factor: 12.531

4.  Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting.

Authors:  M Bregni; M Bernardi; P Servida; A Pescarollo; R Crocchiolo; E Treppiedi; P Corradini; F Ciceri; J Peccatori
Journal:  Bone Marrow Transplant       Date:  2009-02-23       Impact factor: 5.483

5.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

6.  Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells.

Authors:  Yoshiyuki Takahashi; Nanae Harashima; Sachiko Kajigaya; Hisayuki Yokoyama; Elena Cherkasova; J Philip McCoy; Ken-Ichi Hanada; Othon Mena; Roger Kurlander; Abdul Tawab; Tawab Abdul; Ramaprasad Srinivasan; Andreas Lundqvist; Elizabeth Malinzak; Nancy Geller; Michael I Lerman; Richard W Childs
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

7.  C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.

Authors:  Scott S Tykodi; Nobuharu Fujii; Nathalie Vigneron; Sharon M Lu; Jeffrey K Mito; Maureen X Miranda; Jeffrey Chou; Lilien N Voong; John A Thompson; Brenda M Sandmaier; Peter Cresswell; Benoît Van den Eynde; Stanley R Riddell; Edus H Warren
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

8.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Authors:  Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Journal:  Lancet       Date:  2008-07-22       Impact factor: 79.321

9.  Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.

Authors:  Philippe Armand; Supriya Gannamaneni; Haesook T Kim; Corey S Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Ann S LaCasce; Eric D Jacobsen; David C Fisher; Jennifer R Brown; George P Canellos; Arnold S Freedman; Robert J Soiffer; Joseph H Antin
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544
  9 in total
  1 in total

Review 1.  Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.

Authors:  Scott S Tykodi; Brenda M Sandmaier; Edus H Warren; John A Thompson
Journal:  Expert Opin Biol Ther       Date:  2011-03-21       Impact factor: 4.388
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.